DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium

Information source: Rochester General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Delirium; Agitation

Intervention: Risperidone (Drug); Trazodone (Drug); Placebo (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Rochester General Hospital

Official(s) and/or principal investigator(s):
Mindee S Hite, Pharm.D., Principal Investigator, Affiliation: Rochester General Hospital

Overall contact:
Mindee S Hite, Pharm.D., Phone: 585-922-5615, Email: mindee.hite@rochestergeneral.org

Summary

The purpose of this randomized clinical trial is to determine whether risperidone alone, trazodone alone, or a combination of risperidone and trazodone is superior for the treatment of ICU acquired delirium. The hypothesis is that combination therapy is superior to either agent alone in treating ICU acquired delirium and sustaining delirium free time.

Clinical Details

Official title: Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: The number of days patients are without delirium during the study period (delirium-free days)

Secondary outcome:

Daily prevalence of delirium as indicated by a positive Confusion Assessment Method in the ICU (CAM-ICU)

Resolution of delirium as indicated by a negative Confusion Assessment Method in the ICU (CAM-ICU) for more than 24 hours

The number of patients who require rescue medications, the type of rescue medications utilized, and the amount of rescue medications per day

The number of patients who receive sedative agents, amount of midazolam equivalents per day, and the number of days in which patients receive a sedative agent

The number of patients who receive pain medications, amount of fentanyl equivalents per day, and the number of days in which patients receive a pain medication

The number of hours spent agitated (RASS score between +4 and +2) as a percent of the time that the study drug was administered

The number of hours spent excessively sedated or in a coma state (RASS score between -4 to -5) as a percent of the time that the study drug was administered

The duration of mechanical ventilation from initial intubation to extubation as long as the patient remained extubated for more than 48 hours.

The number of days that the patients were alive and breathing without assistance during the study period (ventilator-free days)

The number of episodes and number of patients who experience clinically significant QTc prolongation (≥ 500 msec or an increase of more than 60 msec from baseline)

The number of episodes and number of patients who experience clinically significant extrapyramidal effects (as evidenced by a positive Simpson-Angus Scale Score)

All-cause mortality and 28-day mortality

Detailed description: Delirium is defined as a disturbance of consciousness characterized by an acute onset of impaired cognitive function. Although delirium is thought to be common in the Intensive Care Unit (ICU) there are few studies that have evaluated its incidences, risks and outcomes. It has been associated with increased morbidity, and mortality and increased cost to the healthcare system. In addition to the uncertainty of the incidence of ICU delirium, there is a lack of information about the effects that certain pharmacological treatments have on delirious patients. The rationale for this study is to evaluate the efficacy and safety of risperidone alone, trazodone alone, and risperidone plus trazodone for the treatment of delirium in critically ill patients when compared to placebo.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age greater than 18 years old who are admitted for more than 24 hours in the MICU or

SICU

- Patients diagnosed with delirium by primary team (screened positive for delirium

using the CAM-ICU or with clinical manifestations of delirium)

- Patients have an order for as-needed haloperidol or have received a one-time dose of

haloperidol within 24 hours of randomization

- Patients must be tolerating enteral feeding (greater than 20 mL/hour for more than 12

hours) Exclusion Criteria:

- Patients who are unlikely to survive 24 hours after admission to the ICU

- Patients who are admitted with a primary neurological condition or injury (i. e.

stroke, active seizures, prolonged coma, overdose)

- Patients who can not actively participate in delirium assessment

- Patients actively withdrawing from alcohol or narcotics

- Patients who were treated with any antipsychotic or trazodone within 30 days prior to

ICU admission

- Patients with a marked baseline prolongation of the QTc interval (repeated

demonstration of QTc interval greater 500 milliseconds (msec))

- Patients with a history of Torsades de Pointes

- Patients with current treatment with an agent having either the potential to affect

or increase the risk of QTc prolongation (e. g. erythromycin, any class Ia, Ic, or III antiarrhythmics)

- Patients being treated with a neuromuscular blocker

- Patients in whom haloperidol, risperidone, or trazodone is contraindicated

- Pregnant patients or patients who are breast-feeding

- Patients with a modified Blessed dementia rating scale score ≥4 or an Informant

Questionnaire of Cognitive Dysfunction in the Elderly Score ≥4

- Patients in which informed consent can not be obtained from the legally authorized

representative

Locations and Contacts

Mindee S Hite, Pharm.D., Phone: 585-922-5615, Email: mindee.hite@rochestergeneral.org

Rochester General Hospital, Rochester, New York 14621, United States; Recruiting
Mindee S Hite, Pharm.D., Principal Investigator
Additional Information

Starting date: March 2011
Last updated: April 16, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017